arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Esperion Therapeutics, Inc.

ESPR
$3.19 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
52
Health
Fair
Bearish
auto_awesome

Analytical Summary

Esperion Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $801.8M
Dividend Yield —
Revenue Growth 23.2% ↘
Op. Margin -8.2% ↘
ROIC 1.7% ↗
FCF / Share $-0.11
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Jul 10, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$80.10M
↑ +23.2% —
Net Income Profit after all expenses
$-25.20M
↑ +37.7% —
Operating Margin Operating profit as % of sales
-8.2%
↓ -116.2% 67th
FCF / Share Free cash flow per share
$-0.11
↑ +3.8% —
Long-Term Debt Long-term obligations
$140.00K
↓ -76.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
35
Returns ↓
60
Financial Health
68
Cash Quality ↓
43

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters